Evotec, Genentech Enter Drug Discovery Alliance

Evotec AG has entered into a multi-year integrated drug discovery alliance with Genentech to discover novel small molecule therapeutics.

Evotec will apply its drug discovery platform together with its disease biology expertise against targets selected by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology. The collaboration aims to deliver high quality leads and development candidates to support Genentech’s research efforts.

Dr. Werner Lanthaler, chief executive officer of Evotec, said, “We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec’s scientists and innovative drug discovery platform to support their research efforts. We look forward to working closely with Genentech’s scientists and achieving success together.”